Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers

Long‐acting third‐generation dihydropyridine calcium channel blockers (CCBs) improve endothelial dysfunction and prevent cardiovascular events in humans, but their cellular and molecular mechanisms of tissue protection are not elucidated in detail. We assessed organ (renal) protection by the highly lipophilic CCB lercanidipine in a double‐transgenic rat (dTGR) model with overexpression of human renin and angiotensinogen genes. We randomly treated dTGR with lercanidipine (2.5 mg/kg/day;n=20) or vehicle (n=20) for 3 wk. Furthermore, we explored the influence of lercanidipine on protein kinase C (PKC) signaling in vivo and in vitro using endothelial and vascular smooth muscle cell cultures. Cumulative mortality was 60% in untreated dTGR, whereas none of the lercanidipine‐treated animals died (P< 0.001). We found significantly less albuminuria and improved renal function in lercanidipine‐treated dTGR (both P<0.05). Lercanidipine treatment also significantly (P<0.05) reduced blood levels of the endogenous NOS inhibitor asymmetric dimethylarginine. On histological examination, we observed significantly less tissue inflammation and fibrosis in lercanidipine‐treated animals (both P<0.05). Lercanidipine significantly inhibited angiotensin (ANG) I‐mediated PKC‐α and ‐δ activation in vivo and in vitro, partly due to reduced intracellular calcium flux. As a result, lercanidipine improved endothelial cell permeability in vitro. Lercanidipine prevents tissue injury and improves survival in a model of progressive organ damage. These effects may result, at least in part, from inhibition of tissue inflammation as well as improved NO bioavailability. Modulation of PKC activity may be an important underlying intracellular mechanism.—Menne, J., Park, J.‐K., Agrawal, R., Lindschau, C., Kielstein, J. T., Kirsch, T., Marx, A., Muller, D., Bahlmann, F. H., Meier, M., Bode‐Böger, S. M., Haller, H., Fliser, D. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. FASEB J. 20, E150–E159 (2006)

[1]  J. Lim,et al.  VCAM-1 upregulation via PKCδ-p38 kinase-linked cascade mediates the TNF-α-induced leukocyte adhesion and emigration in the lung airway epithelium , 2005 .

[2]  H. Haller,et al.  Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. , 2004, Diabetes.

[3]  R. Strieter,et al.  Interleukin-7 and Transforming Growth Factor-β Play Counter-regulatory Roles in Protein Kinase C-δ-dependent Control of Fibroblast Collagen Synthesis in Pulmonary Fibrosis* , 2004, Journal of Biological Chemistry.

[4]  J. Cooke.  Asymmetrical Dimethylarginine: The Über Marker? , 2004, Circulation.

[5]  T. Hewett,et al.  PKC-α regulates cardiac contractility and propensity toward heart failure , 2004, Nature Medicine.

[6]  D. Tsikas,et al.  Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans , 2004, Circulation.

[7]  S. Bode-Böger,et al.  Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and citrulline in human plasma and urine applying liquid chromatography-mass spectrometry with very straightforward sample preparation. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[8]  P. Tsao,et al.  Dimethylarginine Dimethylaminohydrolase Regulates Nitric Oxide Synthesis: Genetic and Physiological Evidence , 2003, Circulation.

[9]  R. Berkels,et al.  Vascular Protective Effects of Dihydropyridine Calcium Antagonists , 2003, Pharmacology.

[10]  L. Ghiadoni,et al.  Calcium Antagonist Treatment by Lercanidipine Prevents Hyperpolarization in Essential Hypertension , 2003, Hypertension.

[11]  P. Vallance,et al.  S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W. Kolch,et al.  Induction of Apoptosis by Protein Kinase Cδ Is Independent of Its Kinase Activity* , 2002, The Journal of Biological Chemistry.

[13]  T. Lehtimäki,et al.  Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine , 2001, The Lancet.

[14]  C. Zoccali,et al.  Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.

[15]  Jun-Hyun Yoo,et al.  Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. , 2001, Atherosclerosis.

[16]  L. Platanias,et al.  Protein Kinase C-δ Regulates Thrombin-Induced ICAM-1 Gene Expression in Endothelial Cells via Activation of p38 Mitogen-Activated Protein Kinase , 2001, Molecular and Cellular Biology.

[17]  G. Jerums,et al.  Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. , 2001, Clinical science.

[18]  G. Váradi,et al.  A Ca2+-Dependent Transgenic Model of Cardiac Hypertrophy: A Role for Protein Kinase C&agr; , 2001 .

[19]  F. Amenta,et al.  Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. , 2000, The Journal of pharmacology and experimental therapeutics.

[20]  M. Gollasch,et al.  Protein kinase Cα targeting is regulated by temporal and spatial changes in intracellular free calcium concentration [Ca2+]i , 2000 .

[21]  D. Ganten,et al.  Blood pressure-independent effects in rats with human renin and angiotensinogen genes. , 2000, Hypertension.

[22]  G. Gaviraghi,et al.  Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-alpha on endothelial cells. , 1999, Journal of hypertension.

[23]  H. Fukui,et al.  [Identification of PKC isozymes and effect of knockdown of PKC alpha by antisense oligodeoxynucleotide on iNOS expression via interleukin-1 receptor in vascular smooth muscle cells]. , 1999, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[24]  G. Oriji.  Angiotensin II-induced ET and PGI2release in rat aortic endothelial cells is meditated by PKC , 1999 .

[25]  F. Luft,et al.  Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C. , 1999, Circulation.

[26]  S. Bode-Böger,et al.  Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. , 1999, Journal of the American Society of Nephrology : JASN.

[27]  F. Ruschitzka,et al.  A rationale for treatment of endothelial dysfunction in hypertension. , 1999, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[28]  P. Tsao,et al.  Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. , 1998, Circulation.

[29]  M. Drab,et al.  Endothelial-cell permeability and protein kinase C in pre-eclampsia , 1998, The Lancet.

[30]  R. Dietz,et al.  High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. , 1997, Circulation research.

[31]  E. Ritz,et al.  Inhibitory effect of calcium channel blockers on human mesangial cell growth: evidence for actions independent of L-type Ca2+ channels. , 1996, Kidney international.

[32]  S. Klahr,et al.  Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. , 1995, Kidney international.

[33]  F. Luft,et al.  Nuclear calcium signaling is initiated by cytosolic calcium surges in vascular smooth muscle cells. , 1994, Kidney international.

[34]  F. Luft,et al.  Platelet-derived growth factor and angiotensin II induce different spatial distribution of protein kinase C-alpha and -beta in vascular smooth muscle cells. , 1994, Hypertension.

[35]  Hermann Hailer.  Calcium antagonists and cellular mechanisms of glomerulosclerosis and atherosclerosis. , 1993 .

[36]  Y. Nishizuka.  Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. , 1992, Science.

[37]  R. Alexander,et al.  Angiotensin II-stimulated Na+/H+ exchange in cultured vascular smooth muscle cells. Evidence for protein kinase C-dependent and -independent pathways. , 1987, The Journal of biological chemistry.

[38]  J. Lim,et al.  VCAM-1 upregulation via PKCdelta-p38 kinase-linked cascade mediates the TNF-alpha-induced leukocyte adhesion and emigration in the lung airway epithelium. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[39]  T. Hewett,et al.  PKC-alpha regulates cardiac contractility and propensity toward heart failure. , 2004, Nature medicine.

[40]  J. Dernedde,et al.  The interaction of protein kinase C isozymes alpha, iota, and theta with the cytoplasmic domain of L-selectin is modulated by phosphorylation of the receptor. , 2004, The Journal of biological chemistry.

[41]  R. Strieter,et al.  Interleukin-7 and transforming growth factor-beta play counter-regulatory roles in protein kinase C-delta-dependent control of fibroblast collagen synthesis in pulmonary fibrosis. , 2004, The Journal of biological chemistry.

[42]  W. Kolch,et al.  Induction of apoptosis by protein kinase C delta is independent of its kinase activity. , 2002, The Journal of biological chemistry.

[43]  L. Platanias,et al.  Protein kinase C-delta regulates thrombin-induced ICAM-1 gene expression in endothelial cells via activation of p38 mitogen-activated protein kinase. , 2001, Molecular and cellular biology.

[44]  G. Váradi,et al.  A Ca(2+)-dependent transgenic model of cardiac hypertrophy: A role for protein kinase Calpha. , 2001, Circulation.

[45]  M. Gollasch,et al.  Protein kinase calpha targeting is regulated by temporal and spatial changes in intracellular free calcium concentration [Ca(2+)](i). , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  G. Oriji.  Angiotensin II-induced ET and PGI2 release in rat aortic endothelial cells is mediated by PKC. , 1999, Prostaglandins, leukotrienes, and essential fatty acids.

[47]  D. Ganten,et al.  Hypertension-induced end-organ damage : A new transgenic approach to an old problem. , 1999, Hypertension.

[48]  J. Ménard,et al.  High human renin hypertension in transgenic rats. , 1997, Hypertension.

[49]  K. Hilgers,et al.  Role of angiotensin II in glomerular injury: lessons from experimental and clinical studies. , 1996, Kidney & blood pressure research.

[50]  C. Garrote,et al.  [Calcium antagonists]. , 1995, Enfermeria intensiva.

[51]  H. Haller.  Calcium antagonists and cellular mechanisms of glomerulosclerosis and atherosclerosis. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[52]  M. J. Holtzman,et al.  Interferon- (cid:1) -induced Epithelial ICAM-1 Expression and Monocyte Adhesion INVOLVEMENT OF PROTEIN KINASE C-DEPENDENT c-Src TYROSINE KINASE ACTIVATION PATHWAY* , 2022 .

[53]  G. Dorn,et al.  Protein Kinase C (cid:1) Negatively Regulates Systolic and Diastolic Function in Pathological Hypertrophy , 2022 .